The cardiac neural stem cell phenotype is compromised in streptozotocin-induced diabetic cardiomyopathy.
Neural stem cells were identified in the rat heart and during scar formation and healing participated in sympathetic fiber sprouting and angiogenesis. In the setting of diabetes, impaired wound healing represents a typical pathological feature. These findings provided the impetus to test the hypothesis that experimental diabetes adversely influenced the phenotype of cardiac neural stem cells. Streptozotocin (STZ)-induced diabetic rats were associated with elevated plasma glucose levels, significant loss of body weight and left ventricular contractile dysfunction. In the heart of STZ-diabetic rats, the density of nestin immunoreactive processes emanating from cardiac neural stem cells were reduced. The latter finding was reaffirmed as nestin protein expression was significantly decreased in the heart of STZ-diabetic rats and associated with a concomitant reduction of nestin mRNA. Employing the TUNEL assay, the loss of nestin expression in STZ-diabetic rats was not attributed to widespread cardiac neural stem cell apoptosis. Insulin administration to STZ-diabetic rats with established hyperglycaemia led to a modest recovery of nestin protein expression in cardiac neural stem cells. By contrast, the administration of insulin immediately after STZ injection improved plasma glucose levels and significantly attenuated the loss of nestin protein expression. These data highlight the novel observation that nestin protein expression in cardiac neural stem cells was significantly reduced in STZ-induced type I diabetic rats. The aberrant cardiac neural stem cell phenotype may compromise their biological role and predispose the diabetic heart to maladaptive healing following ischemic injury.
El-Helou
Viviane
V
Département de Physiologie, Université de Montréal, Montréal, Québec, Canada.
Proulx
Cindy
C
Béguin
Pauline
P
Assimakopoulos
John
J
Gosselin
Hugues
H
Clement
Robert
R
Villeneuve
Louis
L
Huot-Marchand
Julie-Emilie
JE
Deblois
Denis
D
Lajoie
Claude
C
Calderone
Angelino
A
D000818:Animals; D017209:Apoptosis / Q000502:physiology; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D001835:Body Weight; D009202:Cardiomyopathies / Q000209:etiology / Q000473:pathology; D003907:Dexamethasone / Q000494:pharmacology; D003921:Diabetes Mellitus, Experimental / Q000150:complications / Q000473:pathology; D005938:Glucocorticoids / Q000494:pharmacology; D006801:Humans; D007328:Insulin / Q000378:metabolism; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism; D008297:Male; D009206:Myocardium / Q000166:cytology*; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism; D064231:Nestin; D009474:Neurons / Q000166:cytology* / Q000502:physiology; D009929:Organ Size; D010641:Phenotype; D051381:Rats; D017207:Rats, Sprague-Dawley; D011924:Rats, Zucker; D013234:Stem Cells / Q000166:cytology / Q000502:physiology*; D016277:Ventricular Function, Left / Q000502:physiology; D020257:Ventricular Remodeling
D001786:Blood Glucose; D005938:Glucocorticoids; D007328:Insulin; D007381:Intermediate Filament Proteins; C577484:NES protein, human; D009419:Nerve Tissue Proteins; C577486:Nes protein, rat; D064231:Nestin; D003907:Dexamethasone